Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Medigus stock

Learn how to easily invest in Medigus stock.

Medigus Ltd is a medical devices business based in the US. Medigus shares (MDGS) are listed on the NASDAQ and all prices are listed in US Dollars. Medigus employs 39 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Medigus

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MDGS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Medigus stock price (NASDAQ: MDGS)

Use our graph to track the performance of MDGS stocks over time.

Medigus shares at a glance

Information last updated 2022-01-25.
Latest market close$0.98
52-week range$0.90 - $3.77
50-day moving average $1.13
200-day moving average $1.51
Wall St. target priceN/A
PE ratio 2.0457
Dividend yield N/A (0%)
Earnings per share (TTM) $0.48

Buy Medigus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Medigus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Medigus price performance over time

Historical closes compared with the close of $0.9799 from 2022-01-25

1 week (2022-01-19) -2.01%
1 month (2021-12-23) -5.78%
3 months (2021-10-26) -34.23%
6 months (2021-07-26) -43.68%
1 year (2021-01-26) -73.08%
2 years (2020-01-24) -47.60%
3 years (2019-01-25) 2.29
5 years (2017-01-26) 84.85%

Is Medigus stock undervalued or overvalued?

Valuing Medigus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medigus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Medigus's P/E ratio

Medigus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Medigus shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Medigus financials

Revenue TTM $2.9 million
Gross profit TTM $-503,000
Return on assets TTM -14.18%
Return on equity TTM 13.89%
Profit margin 281.06%
Book value $2.17
Market capitalisation $23.4 million

TTM: trailing 12 months

Medigus share dividends

We're not expecting Medigus to pay a dividend over the next 12 months.

Have Medigus's shares ever split?

Medigus's shares were split on a 1:4 basis on 15 July 2018. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Medigus shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Medigus shares which in turn could have impacted Medigus's share price.

Medigus share price volatility

Over the last 12 months, Medigus's shares have ranged in value from as little as $0.896 up to $3.77. A popular way to gauge a stock's volatility is its "beta".

MDGS.US volatility(beta: 2.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medigus's is 2.077. This would suggest that Medigus's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Medigus overview

Medigus Ltd. , a medical device company, develops, produces, and markets minimally invasive endo-surgical tools with direct visualization technology in the United States, the United Kingdom, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; develops and commercializes online and offline event planning software, as well as ticketing solutions; and operates online stores for the sale of various consumer products on the Amazon online marketplace. The company was incorporated in 1999 and is headquartered in Omer, Israel. .

Frequently asked questions

What percentage of Medigus is owned by insiders or institutions?
Currently 1.874% of Medigus shares are held by insiders and 2.644% by institutions.
How many people work for Medigus?
Latest data suggests 39 work at Medigus.
When does the fiscal year end for Medigus?
Medigus's fiscal year ends in December.
Where is Medigus based?
Medigus's address is: No. 7A, Omer Industrial Park, Omer, Israel, 8496500
What is Medigus's ISIN number?
Medigus's international securities identification number is: US58471G3002
What is Medigus's CUSIP number?
Medigus's Committee on Uniform Securities Identification Procedures number is: 58471G102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site